Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit

Translational Stroke Research

Volumn 7, Issue 3, 2016, Pages 220-227

  Munakata, Akira ^a   Naraoka, Masato ^a   Katagai, Takeshi ^a   Shimamura, Norihito ^a   Ohkuma, Hiroki ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Celecoxib; Cerebral vasospasm; Cyclooxygenase 2; Endothelin 1; Nitric oxide; Subarachnoid hemorrhage

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BRAIN VASOSPASM; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MORBIDITY; MORTALITY; MORTALITY RATE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT MODEL; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; UPREGULATION; ANIMAL; COMPLICATION; DISEASE MODEL; LEPORIDAE; METABOLISM; PHYSIOLOGY; VASOSPASM, INTRACRANIAL;

ANIMALS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; NITRIC OXIDE; RABBITS; SUBARACHNOID HEMORRHAGE; UP-REGULATION; VASOSPASM, INTRACRANIAL;

EID: 84962170727     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-016-0466-6     Document Type: Article

References (49)

1. Tso MK, Macdonald RL. Subarachnoid hemorrhage: a review of experimental studies on the microcirculation and the neurovascular unit. Transl Stroke Res. 2014;5:174–89.
2. Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4:432–46.
3. Suzuki H. What is early brain injury? Transl Stroke Res. 2015;6:1–3.
4. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med. 2011;17:439–47.
5. Zhang JH. Vascular neural network in subarachnoid hemorrhage. Transl Stroke Res. 2014;5:423–8.
6. Li Q, Khatibi N, Zhang JH. Vascular neural network: the importance of vein drainage in stroke. Transl Stroke Res. 2014;5:163–6.
7. Etminan N. Aneurysmal subarachnoid hemorrhage—status quo and perspective. Transl Stroke Res. 2015;6:167–70.
8. Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke. 2007;38:1831–6.
9. Crowley RW, Medel R, Dumont AS, Ilodigwe D, Kassell NF, Mayer SA, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke. 2011;42:919–23.
10. Brathwaite S, Macdonald RL. Current management of delayed cerebral ischemia: update from results of recent clinical trials. Transl Stroke Res. 2014;5:207–26.
11. Maeda Y, Tani E, Miyamoto T. Prostaglandin metabolism in experimental cerebral vasospasm. J Neurosurg. 1981;55:779–85.
12. Sasaki T, Murota SI, Wakai S, Asano T, Sano K. Evaluation of prostaglandin biosynthetic activity in canine basilar artery following subarachnoid injection of blood. J Neurosurg. 1981;55:771–8.
13. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991;88:2692–6.
14. Osuka K, Suzuki Y, Watanabe Y, Takayasu M, Yoshida J. Inducible cyclooxygenase expression in canine basilar artery after experimental subarachnoid hemorrhage. Stroke. 1998;29:1219–22.
15. Tran Dinh YR, Jomaa A, Callebert J, Reynier-Rebuffel AM, Tedgui A, Savarit A, et al. Overexpression of cyclooxygenase-2 in rabbit basilar artery endothelial cells after subarachnoid hemorrhage. Neurosurgery. 2001;48:626–33.
16. Desjardins F, Aubin MC, Carrier M, Perrault LP. Decrease of endothelin recepter subtype ETB and release of COX-derived products contribute to endothelial dysfunction of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2005;45:499–508.
17. Zhou Y, Mitra S, Varadharaj S, Parinandi N, Zweier JL, Flavahan NA. Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. Circ Res. 2006;98:1439–45.
18. Hink U, Munzel T. COX-2, another important player in the nitric oxide-endothelin cross-talk: good news for COX-2 inhibitor? Circ Res. 2006;98:1344–6.
19. Pluta RM. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Neurol Res. 2006;28:730–7.
20. Kikkawa Y, Kurogi R, Sasaki T. The single and double blood injection rabbit subarachnoid hemorrhage model. Transl Stroke Res. 2015;6:88–97.
21. Mori K. Double cisterna magna blood injection model of experimental subarachnoid hemorrhage in dogs. Transl Stroke Res. 2014;5:647–52.
22. Wahn H, Wolf J, Kram F, Frantz S, Wagner JA. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol. 2005;289:2491–6.
23. Boiti C, Guelfi G, Brecchia G, Dall’Aglio C, Ceccarelli P, Maranesi M, et al. Role of the endothelin-1 system in the luteolytic process of pseudopregnant rabbits. Endocrinology. 2005;146:1293–300.
24. Boiti C, Zampini D, Guelfi G, Paolocci F, Zerani M, Gobbetti A. Expression patterns of endothelial and inducible nitric oxide synthase isoforms in corpora lutea of pseudopregnant rabbits at different luteal stages. J Endocrinol. 2002;173:285–96.
25. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1107–15.
26. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Investig. 2012;92:1115–28.
27. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in apoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443–52.
28. Jacobs S, Laury-Kleintop L, Lanza-Jacoby S. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E−/− mice. J Surg Res. 2008;146:135–42.
29. Hino A, Tokuyama Y, Weir B, Takeda J, Yano H, Bell GI, et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery. 1996;39:562–7.
30. Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS. Role of endothelial no synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 2005;36:2731–7.
31. Kasuya H, Weir BK, Nakane M, Pollock JS, Johns L, Marton LS, et al. Nitric oxide synthase and guanylate cyclase levels in canine basilar arteries after subarachnoid hemorrhage. J Neurosurg. 1995;82:250–5.
32. Sabri M, Ai J, Knight B, Tariq A, Jeon H, Shang X, et al. Uncoupling of endothelial nitric oxide synthase after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2010;31:190–9.
33. Neuschmelting V, Marbacher S, Fathi AR, Jakob SM, Fandino J. Elevated level of endothelin-1 in cerebrospinal fluid and lack of nitric oxide in basilar arterial plasma associated with cerebral vasospasm after subarachnoid haemorrhage in rabbits. Acta Neurochir (Wien). 2009;151:795–801.
34. Kästner S, Oertel MF, Scharbrodt W, Krause M, Böker DK, Deinsberger W. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien). 2005;147:1271–9.
35. Ohkuma H, Parney I, Megyesi J, Ghahary A, Findlay JM. Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage. J Neurosurg. 1999;90:1105–14.
36. Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery. 1998;43:863–75.
37. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000;92:390–400.
38. Xie A, Aihara Y, Bouryi VA, Nikitina E, Jahromi BS, Zhang ZD, et al. Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2007;27:1692–701.
39. Itoh S, Sasaki T, Asai A, Kuchino Y. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg. 1994;81:759–64.
40. Sproviero D, Julien S, Burford B, Taylor-Papadimitriou J, Burchell JM. Cyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer. J Biol Chem. 2012;287:44490–7.
41. Vivaldi A, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, et al. Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Mol Cell Endocrinol. 2012;355:41–8.
42. Mukherjee K, Gitlin JM, Loftin CD. Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype. J Cardiovasc Pharmacol. 2012;60:520–9.
43. Ohkuma H, Tsurutani H, Suzuki S. Changes of beta-actin mRNA expression in canine vasospastic basilar artery after experimental subarachnoid hemorrhage. Neurosci Lett. 2001;311:9–12.
44. Shimamura N, Ohkuma H. Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage. Transl Stroke Res. 2014;5:357–64.
45. Hald ES, Alford PW. Smooth muscle phenotype switching in blast traumatic brain injury-induced cerebral vasospasm. Transl Stroke Res. 2014;5:385–93.
46. Edvinsson L, Larsen SS, Maddahi A, Nielsen J. Plasticity of cerebrovascular smooth muscle cells after subarachnoid hemorrhage. Transl Stroke Res. 2014;5:365–76.
47. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–80.
48. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–95.
49. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1, e33.